No products in the cart.
Pre-made Vorsetuzumab benchmark antibody ( Whole mAb ADC, anti-CD70/CD27-L therapeutic antibody, Anti-CD27L/LPFS3/CD27LG/TNFSF7/TNLG8A Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-630
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Vorsetuzumab biosimilar, Whole mAb ADC, Anti-CD70/CD27-L Antibody: Anti-CD27L/LPFS3/CD27LG/TNFSF7/TNLG8A therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Vorsetuzumab mafodotin (SGN-75) is an antibody-drug conjugate (ADC) directed to the protein CD70 designed for the treatment of cancer. It is a humanized monoclonal antibody, vorsetuzumab, conjugated with noncleavable monomethyl auristatin F (MMAF), a cytotoxic agent.
| Products Name (INN Index) | Pre-Made Vorsetuzumab biosimilar, Whole mAb ADC, Anti-CD70/CD27-L Antibody: Anti-CD27L/LPFS3/CD27LG/TNFSF7/TNLG8A therapeutic antibody |
|---|---|
| INN Name | Vorsetuzumab |
| Target | CD70 |
| Format | Whole mAb ADC |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2012 |
| Year Recommended | 2013 |
| Companies | Seattle Genetics |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Autoimmune disorders,Cancer,Inflammation,Plaque psoriasis |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CD70 |
| Package |
Previous slide
Next slide
